Monofer (Ferric Derisomaltose)

Ferric derisomaltose delivers iron in a stable carbohydrate complex that circulates in the bloodstream. The complex is taken up by macrophages, where iron is released and bound to transferrin, the transport protein that delivers iron to the bone marrow for hemoglobin synthesis and to other iron‑dependent tissues.

The prescribed dose of Monofer is individualized by the treating clinician based on the patient’s total iron deficit, body weight, hemoglobin level, and clinical condition. The prescriber calculates the required amount of iron to safely correct the deficiency and monitors response during therapy.

Safety data for ferric derisomaltose in pregnancy and lactation are limited. The product should be used only if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To order Monofer, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if needed), and necessary import documentation.

Monofer delivers a large, single‑dose infusion of iron with a stable iron‑carbohydrate complex, allowing rapid repletion with fewer administrations compared with some older IV iron formulations. Its low‑reactivity profile reduces the risk of acute reactions, but clinicians still consider patient‑specific factors when selecting an IV iron product.

Monofer should be stored at 2 °C to 8 °C (refrigerated). Keep the vial in its original packaging, protect it from light, and do not freeze or shake the solution. If the product reaches room temperature, it should be used promptly and not returned to refrigeration.

Monofer is given as an intravenous infusion. The vial is diluted with an appropriate compatible solution and administered through a peripheral or central line over a period determined by the prescriber, typically ranging from a few minutes to an hour, while monitoring the patient for any adverse reactions.

The most serious risks include severe hypersensitivity reactions such as anaphylaxis, acute iron overload leading to organ toxicity, and rare thromboembolic events. Immediate medical attention is required if signs of an allergic reaction, sudden hypotension, or unexplained chest pain occur during or after infusion.

Monofer is contraindicated in patients with known hypersensitivity to ferric derisomaltose or any component of the formulation. It should also be avoided in individuals with active severe infections, uncontrolled cardiac disease, or those who have experienced previous severe reactions to other intravenous iron products.